NO317107B1 - Ny krystallmodifikasjon av torasemid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat - Google Patents

Ny krystallmodifikasjon av torasemid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat Download PDF

Info

Publication number
NO317107B1
NO317107B1 NO20011633A NO20011633A NO317107B1 NO 317107 B1 NO317107 B1 NO 317107B1 NO 20011633 A NO20011633 A NO 20011633A NO 20011633 A NO20011633 A NO 20011633A NO 317107 B1 NO317107 B1 NO 317107B1
Authority
NO
Norway
Prior art keywords
torasemide
crystal modification
crystal
modification
acid
Prior art date
Application number
NO20011633A
Other languages
English (en)
Norwegian (no)
Other versions
NO20011633D0 (no
NO20011633L (no
Inventor
Darko Filic
Miljenko Dumic
Aleksandar Danilovski
Bozena Klepic
Ines Fistric
Marina Oresic
Jasna Horvat Mikulcic
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10946825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO317107(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of NO20011633D0 publication Critical patent/NO20011633D0/no
Publication of NO20011633L publication Critical patent/NO20011633L/no
Publication of NO317107B1 publication Critical patent/NO317107B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal (AREA)
  • Liquid Crystal Substances (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20011633A 1998-10-02 2001-03-30 Ny krystallmodifikasjon av torasemid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat NO317107B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR980532A HRP980532B1 (en) 1998-10-02 1998-10-02 Novel crystalline torasemide modification
PCT/HR1999/000023 WO2000020395A1 (en) 1998-10-02 1999-10-01 New crystal modification iii of torasemide

Publications (3)

Publication Number Publication Date
NO20011633D0 NO20011633D0 (no) 2001-03-30
NO20011633L NO20011633L (no) 2001-03-30
NO317107B1 true NO317107B1 (no) 2004-08-09

Family

ID=10946825

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011633A NO317107B1 (no) 1998-10-02 2001-03-30 Ny krystallmodifikasjon av torasemid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat

Country Status (32)

Country Link
US (5) US6399637B1 (zh)
EP (1) EP1117643B1 (zh)
JP (1) JP2002526532A (zh)
KR (1) KR100437307B1 (zh)
CN (1) CN1125049C (zh)
AT (1) ATE286024T1 (zh)
AU (1) AU759291B2 (zh)
BG (1) BG105485A (zh)
BR (1) BR9915018A (zh)
CA (1) CA2345789A1 (zh)
CZ (1) CZ20011031A3 (zh)
DE (2) DE29924789U1 (zh)
DK (1) DK1117643T3 (zh)
EE (1) EE04341B1 (zh)
ES (1) ES2237158T3 (zh)
HK (1) HK1040250B (zh)
HR (1) HRP980532B1 (zh)
HU (1) HUP0104009A3 (zh)
ID (1) ID29931A (zh)
IL (1) IL142150A0 (zh)
NO (1) NO317107B1 (zh)
NZ (1) NZ510898A (zh)
PL (1) PL346975A1 (zh)
PT (1) PT1117643E (zh)
RU (1) RU2210569C2 (zh)
SI (1) SI1117643T1 (zh)
SK (1) SK4232001A3 (zh)
TR (1) TR200100909T2 (zh)
UA (1) UA72895C2 (zh)
WO (1) WO2000020395A1 (zh)
YU (1) YU24001A (zh)
ZA (1) ZA200102451B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6394707B1 (en) 1997-05-08 2002-05-28 Jack Kennedy Metal Products & Buildings, Inc. Yieldable mine roof support
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
CZ2002404A3 (cs) 1999-08-11 2002-06-12 Teva Pharmaceutical Industries Ltd. Polymorfní formy torsemidu
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide
IN192178B (zh) * 2001-08-03 2004-03-06 Ranbaxy Lab
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
JP4406845B2 (ja) * 2007-02-20 2010-02-03 トヨタ自動車株式会社 二次電池電極材の剥離剤及び該剥離剤を用いた二次電池の処理方法
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4055650A (en) * 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
US4473693A (en) 1978-08-04 1984-09-25 Stewart Walter W Aminonaphthalimide dyes for intracellular labelling
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III

Also Published As

Publication number Publication date
AU759291B2 (en) 2003-04-10
AU6224099A (en) 2000-04-26
NO20011633D0 (no) 2001-03-30
KR100437307B1 (ko) 2004-06-25
HUP0104009A2 (hu) 2002-02-28
US20030055258A2 (en) 2003-03-20
HRP980532B1 (en) 2005-06-30
DE69922977T2 (de) 2005-12-08
US6399637B1 (en) 2002-06-04
CN1125049C (zh) 2003-10-22
DE69922977C5 (de) 2008-12-24
ZA200102451B (en) 2001-09-28
CZ20011031A3 (cs) 2001-08-15
WO2000020395A1 (en) 2000-04-13
DE69922977D1 (de) 2005-02-03
US20040229919A1 (en) 2004-11-18
TR200100909T2 (tr) 2001-07-23
BG105485A (en) 2002-01-31
US20060205951A1 (en) 2006-09-14
NZ510898A (en) 2002-10-25
HRP980532A2 (en) 2000-12-31
SI1117643T1 (en) 2005-06-30
EE200100194A (et) 2002-06-17
SK4232001A3 (en) 2001-10-08
DK1117643T3 (da) 2005-03-29
CN1321149A (zh) 2001-11-07
ATE286024T1 (de) 2005-01-15
HUP0104009A3 (en) 2002-04-29
US20070276015A1 (en) 2007-11-29
HK1040250A1 (en) 2002-05-31
KR20010079962A (ko) 2001-08-22
RU2210569C2 (ru) 2003-08-20
ES2237158T3 (es) 2005-07-16
US20020147346A1 (en) 2002-10-10
DE29924789U1 (de) 2005-08-25
PL346975A1 (en) 2002-03-11
US6833379B2 (en) 2004-12-21
EP1117643B1 (en) 2004-12-29
ID29931A (id) 2001-10-25
EP1117643A1 (en) 2001-07-25
NO20011633L (no) 2001-03-30
JP2002526532A (ja) 2002-08-20
BR9915018A (pt) 2001-08-14
HK1040250B (zh) 2004-03-05
IL142150A0 (en) 2002-03-10
EE04341B1 (et) 2004-08-16
UA72895C2 (uk) 2005-05-16
CA2345789A1 (en) 2000-04-13
PT1117643E (pt) 2005-05-31
YU24001A (sh) 2003-02-28

Similar Documents

Publication Publication Date Title
US20070276015A1 (en) Crystal modification of torasemide
NO341013B1 (no) Fremgangsmåte for fremstilling av atazanavirbisulfat,og former derav
US20070238759A1 (en) Novel Polymorph V of Torasemide
EP1272470B1 (en) Amorphous torasemide modification
MXPA01003325A (en) New crystal modification iii of torasemide
CN107074744B (zh) Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用